The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Not your normal spivvy AIMer handing out loads at mates rates prices. Quantity low, price high - as it should be - to align interests.
The Options will vest in three instalments and will have an exercise period of five years. The first tranche
will vest when the closing mid-market share price reaches 7.5 pence or above for three consecutive trading
days. The second tranche will vest when the share price reaches 12.5 pence. The third tranche will vest when
the share price reaches 17.5 pence. .
Volume is derisory for the drop. IMO there's a few trying to test how far it can drop..
The model is still excellent [ recurring rev and insurer marketing]- smart meters are totally different - so that was just a ruse. Insurance!!. I can only assume it has dropped 50% this year as we haven't has new contracts every month, along with a bit of boredom and a bit of botty wobbling.
£15m written off because they are growing cautiously - GLA
They already have a strategic investor lined up , who clearly sees value and wants in.
Very rare opp to get in at the very bottom and acquire a couple of % for peanuts to tuck away
Remember, 11p was the placing price in Dec; the placing where they bit the bullet to get 4 years of funding sorted.
Currently an EV of £3.2m - that's an insane value disconnect for rev generating with world's leading tech. Just under the radar atm
Posted April 21
In Intra's excellent post , few have picked up this huge USP, need & urgency - total reliance on Australian and NZ cows.
"One of these has signed an MTA to look at RUA’s new composite material which, based on its own benchtop trials, it claims is considerably stronger, tear resistant yet thinner and flexible, ideal for TAVR and all improvements over current technologies which rely on animal tissue sourced from cows in Australia and New Zealand, the only BSE-free herds in the world. You can see why the majors will eventually want to develop something new that doesn’t rely on a risky supply chain such as these animals. If BSE invaded Australia, these majors would freak out."
The current mcap [ex cash of £4m] is £4m.
They are not just a one trick pony.
- core business growing and revenues expected to double
- heart value being testing with leading partner with plans to commercialise
-VASCULAR GRAFT developed and looking to partner
No placing for years and NO WARRANTS..
60m shares.
If you can't work this one out, give up!
Agree , good to add quality to the BOD. And balance sheets wise also agree. With last sale instalment and placing, the EV is just £250k - with just 70m shares, easily a parabolic stock if you have a little patience
Very nice having the company underwritten by a strategic investor a] they must see potential b] de-risks the company.
So far impressed with the ambitious yet careful bod.